Partnering with industrial operators is the way to succeed in technology development to transform inventions into successful products for the benefit of patients and public health. The Institut Pasteur and its industrial partners are collaborating to achieve this goal.
Bringing innovative solutions to patients’ unmet needs is a challenge that no single organization is currently capable of achieving. Academic and industrial stakeholders must now rapidly unite their expertise to provide medical, scientific, and technological responses for patient health.
Following its successful involvement in past and current research partnerships, the Institut Pasteur is now intensifying its visibility and availability to attract new industrial partners, from startups to major groups.
What the Institut Pasteur offers
By collaborating with the Institut Pasteur, industry partners can benefit from its extensive range of research fields.
- Joint applications to national and international calls for proposals (IMI, H2020, NIH, CEPI, etc.)
- A 60% research tax credit for which all companies involved in R&D in France are eligible
- Access to the Institute’s cutting-edge technical facilities, such as the Technological Research Platforms (DTPS), Bioinformatics and Biostatistics Hub, Medical Center, and Center for Translational Science (CRT), as well as the Microbiology Technology Institute Bioaster
- And much more if you are part of a strategic alliance partnership
Founded in April 2012 by the Institut Pasteur and Lyonbiopole health competitiveness cluster, following the initiative of the French government, Bioaster Technology Research Institute (TRI) is working to develop a unique technological and innovative model to help face the latest challenges in microbiology, and in particular to:
- Fight antimicrobial resistance
- Improve the safety and efficacy of vaccines. Quickly diagnose infections at the patient’s bedside. Take full advantage of human and animal microbiota.
The aim of Bioaster is to boost the development of medical and nutritional solutions for human and animal health.
Bioaster is supported by high-profile academic and industrial partners. Since it was set up, it has coordinated over 53 research projects with 25 academic partners and 26 industry partners (source: Bioaster).
Between the phases of knowledge acquisition and providing a solution for the patient, Bioaster seeks to act as a bridge between the academic and private spheres, provide technological added value in microbiology, and is an agile and collaborative organization that reduces the risks associated with innovation.
The currently available patents for licensing and tech transfer are listed below. Please consult this document for further details of technologies potentially meeting your needs.